This company listing is no longer active
Aceragen Management
Management criteria checks 3/4
Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
Key information
John Taylor
Chief executive officer
US$444.1k
Total compensation
| CEO salary percentage | 17.5% |
| CEO tenure | less than a year |
| CEO ownership | 17.5% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$444k | US$78k | -US$23m |
Compensation vs Market: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Taylor (52 yo)
less than a year
Tenure
US$444,062
Compensation
Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Associate Director of Human Resources | no data | no data | no data | |
| Director of Human Resources | no data | no data | no data | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Global Head of Quality | no data | no data | no data | |
| Medical Director & Global Clinical Lead for Oncology | no data | no data | no data | |
| Advisor | 4.1yrs | US$993.93k | no data | |
| Adviser | no data | US$986.13k | no data |
4.1yrs
Average Tenure
62yo
Average Age
Experienced Management: ACGN's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Independent Director | 4.3yrs | US$89.43k | 0.26% $ 8.4k | |
| Chair of the Board of Directors | 8.7yrs | US$1.43m | 0.10% $ 3.2k | |
| Independent Director | less than a year | US$11.88k | no data | |
| Independent Director | 7.6yrs | US$66.24k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$60.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisor Board | no data | no data | 14.31% $ 458.0k |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ACGN's board of directors are considered experienced (4.3 years average tenure).